Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
With
Regeneron Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with non-Hodgkin B-cell lymphoma, good condition, not previously treated
You may not be if
Contraindication to any drug contained in the R-CHOP (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/- intrathecal Methotrexate)
Less than 42 days elapsed from prior major surgery (28 days from other prior surgery) to the time of inclusion
Cerebral or leptomeningeal involvement.
History of another neoplasm (Adequately treated basal cell or squamous cell skin cancers, carcinoma in situ of the cervix, or any other cancer from which the patient has been disease free for \> 5 years are allowed)
Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to the first drug intake
Any acute or chronic medical condition, which could impair the ability of the patient to participate to the study or could interfere with interpretation of study results
Uncontrolled diabetes mellitus
Uncontrolled hypertension
Abnormal kidney function
Evidence of clinically significant bleeding diathesis, non-healing wound or underlying coagulopathy
Pregnant or breast-feeding woman, or patient with reproductive potential (male, female) without an effective method of contraception
History of hypersensitivity to any Trap agents or recombinant proteins
Clareo Health | Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
